Vortex Keratopathy in a Patient Receiving Vandetanib for Non-Small Cell Lung Cancer.
10.3341/kjo.2011.25.5.355
- Author:
Jeeyun AHN
1
;
Won Ryang WEE
;
Jin Hak LEE
;
Joon Young HYON
Author Information
1. Department of Ophthalmology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. jyhyon@snu.ac.kr
- Publication Type:Case Report
- Keywords:
Epidermal growth factor;
Vandetanib;
Vortex keratopathy
- MeSH:
Adult;
Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology;
Cornea/drug effects/*pathology;
Corneal Diseases/*chemically induced/diagnosis;
Diagnosis, Differential;
Dose-Response Relationship, Drug;
Female;
Follow-Up Studies;
Humans;
Lung Neoplasms/*drug therapy/pathology;
Microscopy, Acoustic;
Piperidines/administration & dosage/*adverse effects;
Quinazolines/administration & dosage/*adverse effects;
Visual Acuity
- From:Korean Journal of Ophthalmology
2011;25(5):355-357
- CountryRepublic of Korea
- Language:English
-
Abstract:
We report a case of vortex keratopathy in a patient treated with vandetanib for non-small cell lung cancer (NSCLC). A 44-year-old female who underwent two cycles of chemotherapy for NSCLC complained of visual blurring in both eyes after the initiation of vandetanib, an anti-epidermal growth factor receptor (EGFR) and anti-vascular endothelial growth factor receptor 2 protein tyrosine kinase inhibitor. On ophthalmic examination, visual acuities were 20 / 20 OU and, with the exception of diffuse vortex keratopathy in both eyes, other findings were unremarkable. Vandetanib is believed to have caused vortex keratopathy in this patient. Anti-EGFR properties affecting normal corneal epithelial cell migration and wound healing or drug associated metabolite deposition, which is the case in numerous drug-associated vortex keratopathies, may be possible underlying mechanisms in the formation of this corneal complication.
